Gas6 blockade stops fatal thrombosis

Gas6 is a platelet-response amplifier that, if inhibited, protects from thrombosis without inducing bleeding. Deep vein thrombosis (DVT) is a common condition that can be fatal if fractions of the clot break off and lodge in the arteries of the lungs. Heparin, warfarin and aspirin prevent clot formation but may induce bleeding.In the February Nature Medicine researchers from the Centre for Transgene technology and Gene Therapy at Flanders Interuniversity Institute for Biotechnology, Belgium, de

By | February 2, 2001

Gas6 is a platelet-response amplifier that, if inhibited, protects from thrombosis without inducing bleeding. Deep vein thrombosis (DVT) is a common condition that can be fatal if fractions of the clot break off and lodge in the arteries of the lungs. Heparin, warfarin and aspirin prevent clot formation but may induce bleeding.

In the February Nature Medicine researchers from the Centre for Transgene technology and Gene Therapy at Flanders Interuniversity Institute for Biotechnology, Belgium, describe a potential new target for the development of anti-thrombotic drugs.

Anne Angelillo-Scherrer and colleagues found that when the gene coding for a vitamin K-dependent protein called growth arrest-specific gene 6 product (Gas6) is inactivated mice do not suffer fatal blood clotting. In addition the mice do not suffer from excessive bleeding (Nat Med 2001, 7:215-221).

Antibodies against Gas6 inhibited platelet aggregation in vitro and protected mice against fatal thrombosis, suggesting Gas6 as a target for new, 'smart', anti-thrombotic drugs.

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech